Addison Advisors’s AbbVie ABBV Stock Holding History

Addison Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Sell	805 -4,013	-83%	-$863K	0.1%	117
2026 Q1	$1.05M	Buy	4,818 +1	+0%	+$222	0.23%	79
2025 Q4	$1.1M	Buy	4,817 +10	+0.2%	+$2.28K	0.25%	76
2025 Q3	$1.11M	Buy	4,807 +78	+2%	+$15.9K	0.26%	75
2025 Q2	$878K	Buy	4,729 +60	+1%	+$11.2K	0.22%	83
2025 Q1	$978K	Sell	4,669 -10	-0.2%	-$1.94K	0.27%	66
2024 Q4	$831K	Sell	4,679 -113	-2%	-$20.8K	0.23%	74
2024 Q3	$946K	Sell	4,792 -302	-6%	-$56.4K	0.26%	68
2024 Q2	$874K	Buy	5,094 +146	+3%	+$24.2K	0.28%	67
2024 Q1	$901K	Buy	4,948 +429	+9%	+$73.9K	0.31%	67
2023 Q4	$700K	Sell	4,519 -109	-2%	-$15.9K	0.27%	70
2023 Q3	$690K	Buy	4,628 +170	+4%	+$25K	0.32%	65
2023 Q2	$601K	Sell	4,458 -11	-0.2%	-$1.61K	0.3%	68
2023 Q1	$712K	Buy	4,469 +227	+5%	+$34.7K	0.4%	56
2022 Q4	$686K	Sell	4,242 -241	-5%	-$37K	0.41%	52
2022 Q3	$602K	Sell	4,483 -4	-0.1%	-$574	0.37%	55
2022 Q2	$687K	Sell	4,487 -46	-1%	-$7.03K	0.42%	52
2022 Q1	$735K	Buy	4,533 +1,372	+43%	+$199K	0.4%	57
2021 Q4	$428K	Buy	3,161 +705	+29%	+$83.3K	0.26%	73
2021 Q3	$265K	Buy	2,456 +6	+0.2%	+$686	0.21%	64
2021 Q2	$276K	Buy	+2,450	New	+$276K	0.22%	63
2020 Q4	$284K	Buy	+2,650	New	+$255K	0.27%	60

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Addison Advisors's ABBV Position: Q2 2026 in Review

Addison Advisors reduced its AbbVie (ABBV) stake by 83% in Q2 2026, selling an estimated $863K and leaving 805 shares worth $203K. The position accounts for 0.1% of the portfolio, ranked #117.

Addison Advisors first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.11M in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Addison Advisors held 805 shares of AbbVie worth $203K as of Q2 2026.
Addison Advisors sold 4,013 AbbVie shares in Q2 2026, an estimated $863K.
AbbVie made up 0.1% of Addison Advisors's portfolio in Q2 2026, its #117 holding.
Addison Advisors first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
Addison Advisors's AbbVie position peaked at $1.11M in Q3 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.